Michael D. Goldberg is the Board Chairman of XDx.
During a career spanning 30 years, he has been a company founder, CEO, board member and venture capitalist. Michael joined the life science industry in 1981 and participated in the commercialization of the first generation of recombinant DNA, monoclonal antibody and PCR technology. Michael has been a pioneer in developing and building molecular diagnostics companies and has served on the boards of Genomic Health, CardioDx, and Crescendo Bioscience.
Michael joined the XDx board in 2011 to assist in the commercialization AlloMap and to extend the XDx technology platform to other important clinical applications in transplant medicine and immunology.
In addition to his work as a corporate board member and investor, Michael has served on the Board of the California Institute for Regenerative Medicine since its inception in 2005 ($3 billion state stem cell agency).
Michael is also on the advisory councils of the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, the Caltech Division of Biology, and the Berkeley Center for Law and Technology.
He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation.
Michael is a former board member of the Western Association of Venture Capitalists.
Michael holds a BA from Brandeis University.
An MBA from the Stanford Graduate School of Business.